Differentiating features of MPN: Impact on managment, treatment

ByJeanne M. Palmer, MD

In this video, Jeanne M. Palmer, MD, hematologist and oncologist at the Mayo Clinic, discussed:

The disease states and treatment options for myelofibrosis (MF), essential thrombocythemia (ET) and polycythemia vera (PV);
Driver mutations of MF, ET and PV, such as JAK2, MPL and calreticulin (CALR);
The criteria for diagnosing PV, noting that “this disease is often discovered when patients have an elevated red blood cell”; and
Treatment for patients with MF, explaining that this can be very individualized and depends on risk factors and symptom burden.

Click here for more in this video series.

Published by:

Collapse

Source: Healio Interview

Disclosures: Palmer reports no relevant financial disclosures.

MPN Video Perspectives